APOA1 and acute coronary syndrome: The pooled results showed that HDL/apoA-1 replacement therapy use did not significantly decrease the percent atheroma volume (<i>p</i> = 0.766) or total atheroma volume (<i>p</i> = 0.510) in acute coronary syndrome (ACS) patients (<i>N</i> = 754).